104 related articles for article (PubMed ID: 38716585)
1. Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.
Qiao L; He W; Wang G; Chen H; Huang F; Zhang B; Qiu Y; Liu S; Huang Z; Yuan Y; Qiu J; Yuan Y; Li B
Cancer Med; 2024 May; 13(9):e7236. PubMed ID: 38716585
[TBL] [Abstract][Full Text] [Related]
2. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
[TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
5. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
Ogasawara S; Ooka Y; Itokawa N; Inoue M; Okabe S; Seki A; Haga Y; Obu M; Atsukawa M; Itobayashi E; Mizumoto H; Sugiura N; Azemoto R; Kanayama K; Kanzaki H; Maruta S; Maeda T; Kusakabe Y; Yokoyama M; Kobayashi K; Kiyono S; Nakamura M; Saito T; Suzuki E; Nakamoto S; Yasui S; Tawada A; Chiba T; Arai M; Kanda T; Maruyama H; Kato N
Invest New Drugs; 2020 Feb; 38(1):172-180. PubMed ID: 31172442
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
7. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
Yoo C; Park JW; Kim YJ; Kim DY; Yu SJ; Lim TS; Lee SJ; Ryoo BY; Lim HY
Invest New Drugs; 2019 Jun; 37(3):567-572. PubMed ID: 30523474
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China.
Qu W; Liu Z; Chen X; Liu B; Zhao Y; Yan H; Qu X; Li S; Zang A; Sun Y; Zhu L; Zhou A
BMC Cancer; 2024 Jan; 24(1):22. PubMed ID: 38166647
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy combination with regorafenib for refractory hepatocellular carcinoma: A real-world study.
Tu X; Yang J; Zheng Y; Liang C; Tao Q; Tang X; Liu Z; Jiang L; He Z; Xie F; Zheng Y
Int Immunopharmacol; 2022 Dec; 113(Pt B):109401. PubMed ID: 36395672
[TBL] [Abstract][Full Text] [Related]
10. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
11. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey.
Bekir Hacioglu M; Kostek O; Karabulut S; Tastekin D; Sezgin Goksu S; Alandag C; Akagunduz B; Bilgetekin I; Caner B; Bilgehan Sahin A; Yildiz B; Kose F; Kaplan MA; Gulmez A; Dogan E; Can Guven D; Gurbuz M; Ergun Y; Karaagac M; Gokcen Demiray A; Turker S; Sakalar T; Ozkul O; Telli TA; Sahin S; Kilickap S; Bilici A; Erdogan B; Cicin I
J BUON; 2020; 25(4):1897-1903. PubMed ID: 33099930
[TBL] [Abstract][Full Text] [Related]
12. Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma.
Garcia-Reyes K; Gottlieb RA; Menon KM; Bishay V; Patel R; Patel R; Nowakowski S; Sung MW; Marron TU; Gansa WH; Zhang J; Raja SC; Shilo D; Fischman A; Lookstein R; Kim E
J Vasc Interv Radiol; 2024 May; 35(5):722-730.e1. PubMed ID: 38342221
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
Parikh ND; Singal AG; Hutton DW
Cancer; 2017 Oct; 123(19):3725-3731. PubMed ID: 28662266
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
15. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Hong YM; Yoon KT; Cho M
BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib as treatment for patients with advanced hepatocellular cancer.
Thillai K; Srikandarajah K; Ross P
Future Oncol; 2017 Oct; 13(25):2223-2232. PubMed ID: 28766967
[TBL] [Abstract][Full Text] [Related]
17. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
18. A multi-center retrospective study on the efficacy and safety of regorafenib
Yan T; Huang C; Peng C; Duan X; Ji D; Duan Y; Zhang W; Zhao H; Gao K; Yang X; Zhang L; Cheng J; de Castria TB; Pocha C; Tsilimigras DI; Wu T; Su G; Li Y; Yu L; Lu Y
Ann Transl Med; 2023 Jan; 11(2):109. PubMed ID: 36819518
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):611-617. PubMed ID: 29040994
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.
Lee CH; Lee YB; Kim MA; Jang H; Oh H; Kim SW; Cho EJ; Lee KH; Lee JH; Yu SJ; Yoon JH; Kim TY; Kim YJ
Clin Mol Hepatol; 2020 Jul; 26(3):328-339. PubMed ID: 32460459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
